MedTrace Logo

A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

NCT01803035 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2014-04-28

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of the topical antibiotic LTX-109 in terms of clinical and microbiological response in treatment of impetigo.

Conditions

  • Non-bullous Impetigo

Interventions

DRUG

LTX-109 1 %

DRUG

LTX-109 2 %

DRUG

Placebo gel

Sponsors & Collaborators

  • Lytix Biopharma AS

    lead INDUSTRY

Principal Investigators

  • Daisy M Blanco, MD · Institute of Dermatology and Skin Surgery, Dr. Hubert Bogaert Diaz, Santo Domingo

  • Josefina Fernandez, MD · Dr. Robert Reid Cabral Children hospital, Santo Domingo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-03-31
Completion
2014-04-30

Countries

  • Dominican Republic

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01803035 on ClinicalTrials.gov